Sonnet Biotherapeutics Holdings Inc (SONN) - Total Assets
Based on the latest financial reports, Sonnet Biotherapeutics Holdings Inc (SONN) holds total assets worth $2.06 Million USD as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Sonnet Biotherapeutics Holdings Inc - Total Assets Trend (2007–2025)
This chart illustrates how Sonnet Biotherapeutics Holdings Inc's total assets have evolved over time, based on quarterly financial data. Also see market value of Sonnet Biotherapeutics Holdings Inc for the company's overall valuation and market capitalisation.
Sonnet Biotherapeutics Holdings Inc - Asset Composition Analysis
Current Asset Composition (September 2025)
Sonnet Biotherapeutics Holdings Inc's total assets of $2.06 Million consist of 96.4% current assets and 3.6% non-current assets. Review Sonnet Biotherapeutics Holdings Inc (SONN) financial obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 34.4% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2007–2025)
This chart illustrates how Sonnet Biotherapeutics Holdings Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Sonnet Biotherapeutics Holdings Inc stock quote for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sonnet Biotherapeutics Holdings Inc's current assets represent 96.4% of total assets in 2025, an increase from 0.5% in 2007.
- Cash Position: Cash and equivalents constituted 34.4% of total assets in 2025, up from 0.0% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2007.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Sonnet Biotherapeutics Holdings Inc Competitors by Total Assets
Key competitors of Sonnet Biotherapeutics Holdings Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL Ltd
AU:CSL
|
Australia | AU$39.54 Billion |
|
Vaxcyte Inc
NASDAQ:PCVX
|
USA | $3.14 Billion |
|
Bachem Holding AG
SW:BANB
|
Switzerland | CHF2.11 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $1.11 Billion |
|
Chongqing Zhifei Bio Products
SHE:300122
|
China | CN¥29.09 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
China | CN¥6.82 Billion |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
|
China | CN¥3.16 Billion |
Sonnet Biotherapeutics Holdings Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.26 | 1.65 | 1.62 |
| Quick Ratio | 0.26 | 1.65 | 1.62 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-3.78 Million | $2.02 Million | $2.91 Million |
Sonnet Biotherapeutics Holdings Inc - Advanced Valuation Insights
This section examines the relationship between Sonnet Biotherapeutics Holdings Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.07 |
| Latest Market Cap to Assets Ratio | 0.58 |
| Asset Growth Rate (YoY) | 437.1% |
| Total Assets | $14.88 Million |
| Market Capitalization | $8.60 Million USD |
Valuation Analysis
Below Book Valuation: The market values Sonnet Biotherapeutics Holdings Inc's assets below their book value (0.58x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Sonnet Biotherapeutics Holdings Inc's assets grew by 437.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Sonnet Biotherapeutics Holdings Inc (2007–2025)
The table below shows the annual total assets of Sonnet Biotherapeutics Holdings Inc from 2007 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-09-30 | $14.88 Million | +437.15% |
| 2024-09-30 | $2.77 Million | -48.96% |
| 2023-09-30 | $5.43 Million | -6.87% |
| 2022-09-30 | $5.83 Million | -79.89% |
| 2021-09-30 | $28.99 Million | +262.68% |
| 2020-09-30 | $7.99 Million | +20009.69% |
| 2019-09-30 | $39.75K | -99.87% |
| 2018-12-31 | $29.79 Million | -1.29% |
| 2017-09-30 | $30.18 Million | -9.86% |
| 2016-09-30 | $33.49 Million | -20.66% |
| 2015-12-31 | $42.21 Million | +17.92% |
| 2015-09-30 | $35.79 Million | +78.18% |
| 2013-12-31 | $20.09 Million | 0.00% |
| 2013-09-30 | $20.09 Million | +264.92% |
| 2012-09-30 | $5.50 Million | -99.61% |
| 2011-09-30 | $1.41 Billion | +97209.57% |
| 2009-09-30 | $1.45 Million | -34.67% |
| 2008-09-30 | $2.23 Million | -41.82% |
| 2007-09-30 | $3.82 Million | -- |
About Sonnet Biotherapeutics Holdings Inc
As of December 2, 2025, Sonnet BioTherapeutics Holdings, Inc. was acquired by Hyperliquid Strategies Inc, in a reverse merger transaction. Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that bin… Read more